A citation-based method for searching scientific literature

Qiuhua Luo, Ling Zhang, Cong Luo, Mingyan Jiang. Cancer Lett 2019
Times Cited: 20







List of co-cited articles
70 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
25

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright,[...]. N Engl J Med 2018
20

The interplay of immunotherapy and chemotherapy: harnessing potential synergies.
Leisha A Emens, Gary Middleton. Cancer Immunol Res 2015
336
15

Immune checkpoint blockade: a common denominator approach to cancer therapy.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll. Cancer Cell 2015
15

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
15

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.
Leisha A Emens, Paolo A Ascierto, Phillip K Darcy, Sandra Demaria, Alexander M M Eggermont, William L Redmond, Barbara Seliger, Francesco M Marincola. Eur J Cancer 2017
243
15

The future of cancer immunotherapy: microenvironment-targeting combinations.
Yonina R Murciano-Goroff, Allison Betof Warner, Jedd D Wolchok. Cell Res 2020
127
15


Re-polarizing Myeloid-derived Suppressor Cells (MDSCs) with Cationic Polymers for Cancer Immunotherapy.
Wei He, Pei Liang, Guangxing Guo, Zhen Huang, Yiming Niu, Lei Dong, Chunming Wang, Junfeng Zhang. Sci Rep 2016
35
10

The two faces of IL-6 in the tumor microenvironment.
Daniel T Fisher, Michelle M Appenheimer, Sharon S Evans. Semin Immunol 2014
306
10

Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
Fangxuan Li, Yang Zhao, Lijuan Wei, Shixia Li, Juntian Liu. Cancer Biol Ther 2018
47
10


Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
G J Freeman, A J Long, Y Iwai, K Bourque, T Chernova, H Nishimura, L J Fitz, N Malenkovich, T Okazaki, M C Byrne,[...]. J Exp Med 2000
10

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
Sandip Pravin Patel, Razelle Kurzrock. Mol Cancer Ther 2015
10


PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
10

T-cell-Secreted TNFα Induces Emergency Myelopoiesis and Myeloid-Derived Suppressor Cell Differentiation in Cancer.
Mohamad F Al Sayed, Michael A Amrein, Elias D Bührer, Anne-Laure Huguenin, Ramin Radpour, Carsten Riether, Adrian F Ochsenbein. Cancer Res 2019
26
10

Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo.
Zichao Luo, Ce Wang, Huqiang Yi, Ping Li, Hong Pan, Lanlan Liu, Lintao Cai, Yifan Ma. Biomaterials 2015
82
10

Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
Annina M Hafner, Blaise Corthésy, Hans P Merkle. Adv Drug Deliv Rev 2013
111
10

CAR T cell immunotherapy for human cancer.
Carl H June, Roddy S O'Connor, Omkar U Kawalekar, Saba Ghassemi, Michael C Milone. Science 2018
920
10

Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy.
Dangge Wang, Tingting Wang, Jianping Liu, Haijun Yu, Shi Jiao, Bing Feng, Fangyuan Zhou, Yuanlei Fu, Qi Yin, Pengcheng Zhang,[...]. Nano Lett 2016
203
10

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Kristian M Hargadon, Coleman E Johnson, Corey J Williams. Int Immunopharmacol 2018
391
10


Targeting hypoxia in cancer therapy.
William R Wilson, Michael P Hay. Nat Rev Cancer 2011
10

Cytokines in clinical cancer immunotherapy.
Pedro Berraondo, Miguel F Sanmamed, María C Ochoa, Iñaki Etxeberria, Maria A Aznar, José Luis Pérez-Gracia, María E Rodríguez-Ruiz, Mariano Ponz-Sarvise, Eduardo Castañón, Ignacio Melero. Br J Cancer 2019
225
10


Integrating oncolytic viruses in combination cancer immunotherapy.
Praveen K Bommareddy, Megha Shettigar, Howard L Kaufman. Nat Rev Immunol 2018
198
10

Current Challenges in Cancer Treatment.
Jon Zugazagoitia, Cristiano Guedes, Santiago Ponce, Irene Ferrer, Sonia Molina-Pinelo, Luis Paz-Ares. Clin Ther 2016
195
10


Cytokine release syndrome.
Alexander Shimabukuro-Vornhagen, Philipp Gödel, Marion Subklewe, Hans Joachim Stemmler, Hans Anton Schlößer, Max Schlaak, Matthias Kochanek, Boris Böll, Michael S von Bergwelt-Baildon. J Immunother Cancer 2018
519
10

Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
Giuseppe Badalamenti, Daniele Fanale, Lorena Incorvaia, Nadia Barraco, Angela Listì, Rossella Maragliano, Bruno Vincenzi, Valentina Calò, Juan Lucio Iovanna, Viviana Bazan,[...]. Cell Immunol 2019
86
10

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Daniel Y Wang, Joe-Elie Salem, Justine V Cohen, Sunandana Chandra, Christian Menzer, Fei Ye, Shilin Zhao, Satya Das, Kathryn E Beckermann, Lisa Ha,[...]. JAMA Oncol 2018
702
10

Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs.
Rachid Ammi, Jorrit De Waele, Yannick Willemen, Ilse Van Brussel, Dorien M Schrijvers, Eva Lion, Evelien L J Smits. Pharmacol Ther 2015
79
10

Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap.
Wantong Song, Limei Shen, Ying Wang, Qi Liu, Tyler J Goodwin, Jingjing Li, Olekasandra Dorosheva, Tianzhou Liu, Rihe Liu, Leaf Huang. Nat Commun 2018
166
10



Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
Yixin Zhou, Chen Chen, Xuanye Zhang, Sha Fu, Cong Xue, Yuxiang Ma, Wenfeng Fang, Yunpeng Yang, Xue Hou, Yan Huang,[...]. J Immunother Cancer 2018
47
10

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M Samstein, Chung-Han Lee, Alexander N Shoushtari, Matthew D Hellmann, Ronglai Shen, Yelena Y Janjigian, David A Barron, Ahmet Zehir, Emmet J Jordan, Antonio Omuro,[...]. Nat Genet 2019
10


Immunogenic cell death in cancer therapy.
Guido Kroemer, Lorenzo Galluzzi, Oliver Kepp, Laurence Zitvogel. Annu Rev Immunol 2013
10

Oncology meets immunology: the cancer-immunity cycle.
Daniel S Chen, Ira Mellman. Immunity 2013
10

Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, Georgina V Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem,[...]. N Engl J Med 2015
10

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
10

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.
Woonyoung Choi, Sima Porten, Seungchan Kim, Daniel Willis, Elizabeth R Plimack, Jean Hoffman-Censits, Beat Roth, Tiewei Cheng, Mai Tran, I-Ling Lee,[...]. Cancer Cell 2014
908
10

A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors.
Vivek Verma, Tanja Sprave, Waqar Haque, Charles B Simone, Joe Y Chang, James W Welsh, Charles R Thomas. J Immunother Cancer 2018
122
10


Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
Michael A Postow, Robert Sidlow, Matthew D Hellmann. N Engl J Med 2018
10

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Roberto Ferrara, Laura Mezquita, Matthieu Texier, Jihene Lahmar, Clarisse Audigier-Valette, Laurent Tessonnier, Julien Mazieres, Gerard Zalcman, Solenn Brosseau, Sylvestre Le Moulec,[...]. JAMA Oncol 2018
347
10

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.
Lorenzo Galluzzi, Aitziber Buqué, Oliver Kepp, Laurence Zitvogel, Guido Kroemer. Cancer Cell 2015
744
10

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.
Andrea B Apolo, Jeffrey R Infante, Ani Balmanoukian, Manish R Patel, Ding Wang, Karen Kelly, Anthony E Mega, Carolyn D Britten, Alain Ravaud, Alain C Mita,[...]. J Clin Oncol 2017
367
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.